Supply AI

Clinical Trials on a Budget? Supply AI Is Your Secret Weapon

In 2024, the clinical trial industry faces unprecedented challenges and transformations. From economic pressures to resource optimization, the pursuit of cost reduction and efficiency enhancement has become both a corporate survival strategy and a cornerstone for sustainable sector development. While measures like layoffs, process streamlining, and salary adjustments may offer temporary relief, they fail to address the root causes of systemic inefficiencies.

Learn More

Supply AI

Ending Clinical Waste: When Algorithms & Supply Strategies Get Smart

In a novel therapeutic area study, the client opted forACCMED's Depot One warehousing services while delegating drug supply management to a third-party vendor. This operational separation has resulted in multiple unresolved challenges, including: demand forecasting ("how much"), timeline planning ("when"), drug scale-up strategies, and dynamic supply adjustments.

Learn More

Supply AI

Beyond Olympic Fever: Another Arena Sizzles in the Heat!

According to a report by global growth consultancy Frost & Sullivan, the global/Chinese autoimmune drug market is projected to reachUSD 176.7 billion/USD 19.9 billionby 2030, with a2022-2030 CAGR of 3.7%/27.2%.Currently, China’s autoimmune drug market remainsa fraction of theglobalscale, yet it is poised for explosive growth,spurring a surge of strategic investments andproactivemarket entry by pharmaceuticalcompanies.

Learn More

Supply AI

Maximize Impact, Minimize Cost: Supply AI Empowers Precision Management for Clinical Trial Drugs!

In new drug clinical trials, accurately forecasting drug usage is not only the core challenge of research projects but also a critical hurdle for sponsors aiming to reduce costs while enhancing quality. Recognized as an industry-wide conundrum, drug production and procurement forecasting challenges—when marred by delays, disruptions, or errors—inevitably lead to uncertainties in drug supply.

Learn More

ACCMED-IRT

AI Takes the Wheel | Are Clinical Trials Ready?

In clinical studies, systems like EDC, IRT, and eCOA each play their respective roles. But are they truly collaborating seamlessly today? Can current technology frameworks and integration solutions genuinely address the pressing needs for data security, regulatory compliance, and operational agility?

Learn More

ACCMED-IRT

Unveiled: The Untold Truth of Autoimmune Frontiers

Globally, autoimmune diseases (ADs) have emerged as the second-largest therapeutic area, trailing only oncology. In 2022, the global autoimmune disease drug market reached 132.3 billion, projected to surge to 176.7 billion by 2030, with biologics dominating 82.1% of the market. As evidenced by the American Autoimmune Related Diseases Association’s disease registry, the human body harbors over 150 distinct autoimmune conditions.

Learn More

ACCMED-IRT

Randomization ≠ Randomness | A Closer Look at Global Trial Scrutiny

International Clinical Trials Day 520 is just around the corner — Let’s take this opportunity to explore the evolution of clinical trials, starting with the cornerstone of modern study: randomization.

Learn More

ACCMED-eCOA

World Sleep Day | Sleepless Again? You're Not Alone

According to the World Health Organization, approximately 27% of the global population suffers from sleep-related issues. Data from the Chinese Sleep Research Society reveals that over 500 million people in China experience sleep disorders, with the average sleep duration for adults being just 6.75 hours—well below the healthy standard.

Learn More